


# **Considerations for Health Economic Modeling in Phenylketonuria (PKU):** Insights from a Modified Delphi Panel

<sup>1</sup>PTC Therapeutics Sweden AB, Askim, Sweden; <sup>2</sup>Great Ormond Street Hospital for Children, London, UK; <sup>3</sup>Department of Pediatrics, Osaka Metropolitan University School of Medicine, Indianapolis, IN, USA; <sup>5</sup>University Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; <sup>6</sup>Birmingham Children's Hospital, Birmingham, UK; <sup>7</sup>Pediatrics and Metabolism, Department of Pediatrics, Children's Hospital of Nancy, France; <sup>9</sup>Division of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA; <sup>10</sup>Division of Medical Genetics, The University of Texas, USA; <sup>11</sup>Division of Genetics, The University of Texas, USA; <sup>12</sup>Medicus Economics, Boston, MA, USA; <sup>13</sup>PTC Therapeutics Inc, Warren, NJ, USA




| 1. BACKGROUND:   | 4. RESULTS:  |
|--|--|
| Phenylketonuria (PKU) results in elevated blood phenylalanine (Phe) levels, which lead to a wide range of clinical symptoms, including neurocognitive and neurobehavioral impairments. <sup>1</sup>  | Round 1<br>N=11 participants (100%)  |
| Burdensome, lifelong dietary management is required to maintain blood Phe levels within recommended treatment guidelines. <sup>2,3</sup> There is progressive poor adherence with age to Phe-restricted diets <sup>4</sup> leading to suboptimal management of blood Phe levels and the potential for neuropsychological symptoms.   | <ul> <li>completed the survey.</li> <li>≥70% agreement or disagreement (i.e. consensus) was reached on</li> <li>2/14 guestions (Figure)</li> </ul> |
| Currently, two pharmacological therapies have received regulatory approval for the treatment of PKU: sapropterin dihydrochloride and pegvaliase.   | 8/14 questions (Figure,<br>Supplementary table).   |
| <ul> <li>Health technology assessments (HTA) for the reimbursement of sapropterin and pegvaliase have involved varying approaches to cost-effectiveness analysis (CEA). A previous review of these HTA evaluations highlighted a number of limitations with the approaches used,<sup>5</sup> including:</li> <li>Failure to capture long-term impacts of uncontrolled blood Phe</li> </ul> | Intermediate review<br>N=7 (64%) participated in<br>the intermediate review.   |
| <ul> <li>Health state definitions not aligning with utility/cost impacts</li> <li>A lack of support for diet liberalization modeling</li> <li>Implausible or lack of therapy discontinuation modeling</li> <li>An absence of modeling of PKU-associated comorbidities, caregiving impacts, and impacts on mothers and/or unborn children in maternal PKU</li> </ul>                        | The 6 statements not<br>achieving consensus in<br>Round 1, and 1 statement<br>meriting further inquiry,  |
| Given these limitations, consensus on clinically-accurate modeling approaches for CEA would be valuable for assessing novel treatments for PKU.  | were refined into 10<br>statements for Round 2<br>(Figure, Supplementary<br>table).  |
| 2. OBJECTIVE   | <ul> <li>Statement 1 achieved</li> </ul>   |
| This study aimed to identify areas of consensus among PKU medical experts regarding key clinical components for inclusion in a model.  | consensus during the<br>intermediate review; however,<br>participants expressed that<br>the refinements suggested                                  |
| 3. METHODS:  | <ul><li>should be considered in Round 2.</li><li>Changes in participant</li></ul>  |
| Participants For the Delphi panel, purposive sampling was used to recruit experts in order to capture potential heterogeneity in clinical perspectives. <sup>6,7</sup>   | responses on statement 9<br>and statement 14 were not<br>sufficient to change Round 1<br>results.  |
| Eleven participants represented a range of experience (pediatrics, metabolics, genetics; guideline development for PKU; clinical care; clinical study involvement; dietary management) and five countries:   | Round 2  |
|  | N=11 participants (100%) completed the survey.   |
| Preparation<br>Statements for evaluation by the panel were developed with an iterative process<br>encompassing a targeted literature review, expert feedback, a scoping survey. <sup>5,8</sup>   | There was ≥70% agreement or disagreement for 6/10  |
| Process<br>Pilot testing: Conducted with N=4 experts to ensure that the process, instructions, and<br>questions for the survey were clear to the participants.   | revised questions<br>(Figure, Supplementary<br>table).   |
| Round 1: 14-question survey related to clinical outcomes, diet liberalization, unmet need, Phe-level classification, and treatment discontinuation.  | Consensus  |
| <ul> <li>Questions were posed as qualitative statements; participants rated their level of agreement / disagreement using a 5-point Likert scale (plus a "Don't know" option).</li> <li>For some questions, additional details were requested (e.g., quantitative parameters) if the participant agreed or disagreed with the statement.</li> </ul>  | Consensus was achieved on<br>8 of the original statements<br>and 6 revised statements.   |
| Intermediate<br>review: Participants were provided a summary of anonymized responses and<br>encouraged to share further comments via an online forum.  | Consensus could not be achieved on 4 statements.   |
| <b>Round 2:</b> Updated survey with questions that did not achieve consensus in Round 1, refined based on comments from Round 1 responses and the intermediate review.   |  |
| <ul> <li>Consensus was defined as percent agreement or disagreement ≥ 70%.<sup>9,10</sup></li> </ul>   |  |

ACKNOWLEDGMENTS: AC, TH, ML, ACM, DJR, SV, RTZ, FF, NL, HN, and SH received consulting fees from PTC Therapeutics. TO and JJW are employees of Medicus Economics, which received funding from PTC Therapeutics for this work. RZ and IT are employees of PTC Therapeutics and may own stocks in the company. Medical writing and editorial support was provided by Broadstreet HEOR and was funded by PTC Therapeutics. **CONTACT INFORMATION**: Rongrong Zhang - rzhang@ptcbio.com


Rongrong Zhang, MSc;<sup>1</sup> Anupam Chakrapani, MD FRCPCH;<sup>2</sup> Takashi Hamazaki, MD;<sup>5</sup> Danielle J. Ruebel, RDN;<sup>4</sup> Suresh Vijay, MD;<sup>6</sup> Roberto T. Zori, MD;<sup>7</sup> Francois Feillet, MD;<sup>8</sup> Nicola Longo, MD, PhD;<sup>9</sup> Hope Northrup, MD;<sup>10</sup> Suzanne Hollander, MS, RD, LDN;<sup>11</sup> Thomas O'Connell, MA;<sup>12</sup> Jonathan J. Woolley, MSc;<sup>12</sup> Ioannis Tomazos, PhD MBA<sup>13</sup>

| ß                               | <ul> <li>Round 1 – original statements</li> <li>1. An individual patient's blood Phe levels are generally expected to be consistent within certain life stages, including (i) childhood to early adolescence (ages 0-11), (ii) adolescence (ages 12-17), and (iii) adulthood (ages ≥18).</li> </ul> | Round 2 – revised<br>In clinical practice, most patients will generally (other than due to tempora<br>triggers - e.g., fever) remain controlled or uncontrolled within the following<br>age ranges: 0-4 years, 5-11 years, 12-17 years, 18-30 years, >30 years.  |
|---------------------------------|---|--|
| Phe Levels & Associated Outcome | <ol> <li>In real-world management, a realistic (i.e., stable) measurement of a patient's<br/>Phe level may be made in less than 6 months.</li> </ol>  | 100%   |
|                                 | 3. Phe levels of 0-29 umol/L pose a safety risk for patients.   | 73%  |
|                                 | <ol> <li>For patients with Phe levels &lt;120 umol/L, Phe levels higher than 0-29 umol/L<br/>(e.g., 30-60) may pose a safety concern for patients.</li> </ol>   | For patients who are consuming sufficient dietary Phe (i.e., not at risk of nutritional deficiency/growth impairment), Phe levels in the range of 30-12 umol/L may pose a safety concern.  |
|                                 | 5. Sustained uncontrolled Phe levels in a patient's past are associated with intellectual disability.   | 82%  |
|                                 | 6. Sustained uncontrolled Phe levels in a patient's past are associated with outcomes other than intellectual disability.   | The mechanisms below encompass those (both direct and indirect) that account for the association of PKU with chronic comorbidities: high-calor intake from Phe-restricted diet, lack of dietary protein, metabolic abnormalities associated with PKU pathophysiology, metabolic acidosis associated with medical food. |
|                                 | <ol> <li>Controlled vs. uncontrolled blood Phe levels are associated with near-term (e.g.<br/>within 1-4 weeks) likelihood of ADHD / executive-functioning symptoms.</li> </ol>   | . 82%  |
| Liberalization                  | 8. In real-world management, if a patient's Phe levels reached the target range, die<br>liberalization (addition of dietary Phe) would be conducted only if Phe levels<br>remained in the lower half of the target range.   | et If upon initiating a new therapy, a pediatric patient's Phe levels were redu<br>from >360 to consistently 240-299 for three weeks, and the patient<br>expressed desire to consume more dietary Phe, a dietary Phe challenge<br>be conducted.  |
|                                 |   | If upon initiating a new therapy, a pediatric patient's Phe levels were redu<br>from >360 to consistently 300-359 for three weeks, and the patient expres<br>desire to consume more dietary Phe, a dietary Phe challenge may be<br>conducted.  |
| Diet                            | <ol> <li>HRQoL, if considered to include a patient's mental health and psychosocial<br/>functioning, would be expected to improve with addition of 2-3 g of natural prote<br/>to a patient's diet.</li> </ol>   | Medical-food consumption is reduced with increased dietary Phe (protein consumption.   |
| t Need                          | 10. The level of unmet need with the current SoC differs significantly by the 4 sapropterin-experience related subgroups listed (sapropterin naïve, failure, sub-optimally controlled, well-controlled).  | 91%  |
| Unme                            | 11. The level of unmet need with the current SoC differs significantly by other factors (e.g., age, disease severity, pegvaliase response).   | 91%  |
| nt Discontinuation              | 12. Among patients who discontinue sapropterin treatment, negative health outcomes associated with uncontrolled PKU after discontinuation may cause patients to resume sapropterin.   | Among patients who discontinue sapropterin treatment due to sub-optima<br>effectiveness (e.g., Phe levels above target range, or inability to liberalize<br>diet), symptoms of uncontrolled PKU after discontinuation may cause<br>patients to resume sapropterin.   |
|                                 |   | Among patients who discontinue sapropterin treatment due to side effects<br>(e.g., GI discomfort), symptoms of uncontrolled PKU after discontinuation<br>may cause patients to resume sapropterin.   |
|                                 | 13. Among patients who discontinue pegvaliase treatment, negative health outcomes associated with uncontrolled PKU after discontinuation may cause patients to resume pegvaliase.   | Among patients who discontinue pegvaliase treatment due to sub-optima<br>effectiveness (e.g., Phe levels above target range, or inability to liberalize<br>diet), symptoms of uncontrolled PKU after discontinuation may cause<br>patients to resume pegvaliase.   |
| reatme                          |   | Among patients who discontinue pegvaliase treatment due to side effects (e.g., GI discomfort), symptoms of uncontrolled PKU after discontinuation may cause patients to resume pegvaliase.   |
| F                               | 14. Among patients who reach the target blood Phe range with pharmacotherapy,<br>the pharmacotherapy would be continued indefinitely.   | 73%  |
|                                 | Consensus agreement with statement Consensus  | s disagreement with statement ONo consensus achieved on statement  |
|                                 | Abbreviations: ADHD=attention deficit hyperactivity disorder; g=grams; GI=gastrointestinal; H   | RQoL=health-related quality of life; Phe=phenylalanine; PKU=phenylketonuria; SoC=standard of care  |









© 2025 PTC Therapeutics, Inc. All rights reserved

https://www.ncbi.nlm.nih.gov/books/NBK601760/